Loading clinical trials...
Loading clinical trials...
A Post-marketing Observational Study to Assess the Efficacy and Safety of the FVIII/VWF Complex (Human), Alphanate®, in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease
Conditions
Interventions
Alphanate SD/HT
Start Date
September 1, 2007
Primary Completion Date
December 1, 2028
Completion Date
March 1, 2029
Last Updated
August 25, 2023
NCT07115004
NCT04119908
NCT06433778
NCT04677803
NCT03875924
NCT03613584
Lead Sponsor
Grifols Biologicals, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions